NASDAQ:FENC

Fennec Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy FENC

*Your capital is at risk

$9.14

-0.84 (-8.42%)

At Close: Jun 03, 2026

Fennec Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -80.27. In total, the insiders bought 1.25M and sold 1.49M FENC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-80.27
● Buy	1.25M shares
● Sell	1.49M shares
79% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Mar 31, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -80.27. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (79% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 02, 2026 Buy	Stock Options M-Exempt	Raykov Rosty Director	Director	15 598 Value: $38.2K
Mar 02, 2026 Sell	Common shares S-Sale	Raykov Rosty Director	Director	10 079 Value: $84.3K
Feb 28, 2026 Buy	Common shares A-Award	Andrade Robert Chief Financial Officer	C-Suite Officer	1 191 Value: $10.9K
Feb 28, 2026 Buy	Common shares A-Award	Raykov Rosty Director	Director	5 208 Value: $47.6K
Feb 18, 2026 Buy	Common shares M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	2 450 Value: $10K
Feb 18, 2026 Buy	Common shares M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	27 285 Value: $244.7K
Feb 18, 2026 Buy	Common Shares M-Exempt	Hackman Jeffrey S. Chief Executive Officer	CEO / President	13 710 Value: $123.0K
Feb 18, 2026 Buy	Stock Options M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	2 450 Value: $10K
Feb 02, 2026 Buy	Common shares M-Exempt	Raykov Rosty Director	Director	15 598 Value: $38.2K
Feb 02, 2026 Buy	Stock Options M-Exempt	Raykov Rosty Director	Director	15 598 Value: $38.2K
Feb 02, 2026 Sell	Common shares S-Sale	Raykov Rosty Director	Director	10 349 Value: $80.3K
Jan 31, 2026 Buy	Common shares A-Award	Raykov Rosty Director	Director	5 208 Value: $47.6K
Jan 31, 2026 Buy	Common shares A-Award	Andrade Robert Chief Financial Officer	C-Suite Officer	1 558 Value: $14.2K
Jan 23, 2026 Buy	Common shares M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	10 000 Value: $24.5K
Jan 23, 2026 Buy	Stock Options M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	10 000 Value: $24.5K
Jan 15, 2026 Buy	Stock Options M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	10 000 Value: $24.5K
Jan 15, 2026 Buy	Common shares M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	10 000 Value: $24.5K
Jan 07, 2026 Buy	Common shares M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	14 184 Value: $34.8K
Jan 07, 2026 Buy	Stock Options M-Exempt	Andrade Robert Chief Financial Officer	C-Suite Officer	14 184 Value: $34.8K
Jan 02, 2026 Sell	Common shares S-Sale	Raykov Rosty Director	Director	10 312 Value: $78.4K
Jan 02, 2026 Buy	Common shares M-Exempt	Raykov Rosty Director	Director	15 598 Value: $38.2K
Jan 02, 2026 Buy	Stock Options M-Exempt	Raykov Rosty Director	Director	15 598 Value: $38.2K
Dec 31, 2025 Buy	Common shares A-Award	Raykov Rosty Director	Director	5 208 Value: $40.1K
Dec 31, 2025 Buy	Common shares A-Award	Andrade Robert Chief Financial Officer	C-Suite Officer	1 382 Value: $10.6K
Dec 24, 2025 Sell	Common Stock S-Sale	Southpoint Capital Advisors Lp 10 Percent Owner	10% Owner	1 000 000 Value: $7.50M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FENNEC PHARMACEUTICALS, INC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba...

Read Full Profile Here